The risk or severity of adverse effects can be increased when Diclofenamide is combined with Metformin. Metformin may increase the hypoglycemic activities of Insulin Detemir. The therapeutic efficacy of Metformin can be decreased when used in combination with Aripiprazole. The therapeutic efficacy of Metformin can be decreased when used in combination with Hydrocortisone. The therapeutic efficacy of Metformin can be decreased when used in combination with Ziprasidone. Cinoxacin may increase the hypoglycemic activities of Metformin. Toloxatone may increase the hypoglycemic activities of Metformin. Mesterolone may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Pipotiazine. The serum concentration of Dofetilide can be increased when it is combined with Metformin. The risk or severity of adverse effects can be increased when Ethiodized oil is combined with Metformin. Salicylic acid may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Quinethazone. Norfloxacin may increase the hypoglycemic activities of Metformin. Paroxetine may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Prednisone. Pegvisomant may increase the hypoglycemic activities of Metformin. Indalpine may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Verapamil. The therapeutic efficacy of Metformin can be decreased when used in combination with Paliperidone. The therapeutic efficacy of Metformin can be decreased when used in combination with Vorinostat. Phenoxypropazine may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Metolazone. The therapeutic efficacy of Metformin can be decreased when used in combination with Estradiol. Procarbazine may increase the hypoglycemic activities of Metformin. Methyl salicylate may increase the hypoglycemic activities of Metformin. Tranylcypromine may increase the hypoglycemic activities of Metformin. Hydracarbazine may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Chlorothiazide. The therapeutic efficacy of Metformin can be decreased when used in combination with Triptorelin. Selegiline may increase the hypoglycemic activities of Metformin. Metformin may increase the hypoglycemic activities of Mecasermin. The risk or severity of adverse effects can be increased when Brinzolamide is combined with Metformin. The risk or severity of adverse effects can be increased when Acetazolamide is combined with Metformin. Metformin may increase the hypoglycemic activities of Mifepristone. Metformin may increase the hypoglycemic activities of Disopyramide. Zimelidine may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Clozapine. The therapeutic efficacy of Metformin can be decreased when used in combination with Lurasidone. Fluoxymesterone may increase the hypoglycemic activities of Metformin. Fluoxetine may increase the hypoglycemic activities of Metformin. The risk or severity of adverse effects can be increased when Iohexol is combined with Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Leuprolide. Sparfloxacin may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Epinephrine. Metformin may increase the hypoglycemic activities of Quinine. The therapeutic efficacy of Metformin can be decreased when used in combination with Sirolimus. The therapeutic efficacy of Metformin can be decreased when used in combination with Corticotropin. The therapeutic efficacy of Metformin can be decreased when used in combination with Chlorthalidone. Metformin may increase the hypoglycemic activities of Repaglinide. The serum concentration of Metformin can be increased when it is combined with Cimetidine. The risk or severity of adverse effects can be increased when Ethoxzolamide is combined with Metformin. Metformin may increase the hypoglycemic activities of Sulfamethoxazole. The therapeutic efficacy of Metformin can be decreased when used in combination with Asenapine. The therapeutic efficacy of Metformin can be decreased when used in combination with Lopinavir. The therapeutic efficacy of Metformin can be decreased when used in combination with Prednisolone. Alaproclate may increase the hypoglycemic activities of Metformin. The risk or severity of adverse effects can be increased when Methazolamide is combined with Metformin. Nandrolone may increase the hypoglycemic activities of Metformin. Enoxacin may increase the hypoglycemic activities of Metformin. The serum concentration of Metformin can be increased when it is combined with Glycopyrronium. Phenelzine may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Cyclopenthiazide. Pivhydrazine may increase the hypoglycemic activities of Metformin. Duloxetine may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Cyproterone acetate. The therapeutic efficacy of Metformin can be decreased when used in combination with Articaine. The therapeutic efficacy of Metformin can be decreased when used in combination with Ethinyl Estradiol. The serum concentration of Metformin can be increased when it is combined with Bupropion. Sertraline may increase the hypoglycemic activities of Metformin. Metformin may increase the hypoglycemic activities of Insulin Lispro. Nefazodone may increase the hypoglycemic activities of Metformin. Flumequine may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Norgestimate. The therapeutic efficacy of Metformin can be decreased when used in combination with Hydrochlorothiazide. Aminosalicylic Acid may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Everolimus. Nitroaspirin may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Bendroflumethiazide. The serum concentration of Metformin can be increased when it is combined with Dolutegravir. The therapeutic efficacy of Metformin can be decreased when used in combination with Betamethasone. The serum concentration of Trospium can be decreased when it is combined with Metformin. The risk or severity of heart failure can be increased when Pregabalin is combined with Metformin. The risk or severity of adverse effects can be increased when Topiramate is combined with Metformin. Nandrolone decanoate may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Megestrol acetate. The therapeutic efficacy of Metformin can be decreased when used in combination with Indapamide. Citalopram may increase the hypoglycemic activities of Metformin. Rasagiline may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Cortisone acetate. The therapeutic efficacy of Metformin can be decreased when used in combination with Histrelin. Aloxiprin may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Olanzapine. The therapeutic efficacy of Metformin can be decreased when used in combination with Hydroflumethiazide. The therapeutic efficacy of Metformin can be decreased when used in combination with Fludrocortisone. The therapeutic efficacy of Metformin can be decreased when used in combination with Levonorgestrel. The risk or severity of adverse effects can be increased when Iopromide is combined with Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Buserelin. Harmaline may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Nelfinavir. The therapeutic efficacy of Metformin can be decreased when used in combination with Quetiapine. Etoperidone may increase the hypoglycemic activities of Metformin. Trolamine salicylate may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Dienogest. Trovafloxacin may increase the hypoglycemic activities of Metformin. Gemifloxacin may increase the hypoglycemic activities of Metformin. Dapoxetine may increase the hypoglycemic activities of Metformin. Diflunisal may increase the hypoglycemic activities of Metformin. Fleroxacin may increase the hypoglycemic activities of Metformin. Trans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Ceritinib. The therapeutic efficacy of Metformin can be decreased when used in combination with Risperidone. Metformin may increase the hypoglycemic activities of Glyburide. The serum concentration of Metformin can be increased when it is combined with Trimethoprim. The therapeutic efficacy of Metformin can be decreased when used in combination with Estrone sulfate. The therapeutic efficacy of Metformin can be decreased when used in combination with Mestranol. Metformin may increase the hypoglycemic activities of Sunitinib. The therapeutic efficacy of Metformin can be decreased when used in combination with Torasemide. Gatifloxacin may increase the hypoglycemic activities of Metformin. Mebanazine may increase the hypoglycemic activities of Metformin. The therapeutic efficacy of Metformin can be decreased when used in combination with Temsirolimus. Acetylsalicylic acid may increase the hypoglycemic activities of Metformin. Temafloxacin may increase the hypoglycemic activities of Metformin. Desvenlafaxine may increase the hypoglycemic activities of Metformin. Metformin may increase the hypoglycemic activities of Insulin Aspart. Carbaspirin calcium may increase the hypoglycemic activities of Metformin. Metformin may increase the hypoglycemic activities of Tolazamide. The therapeutic efficacy of Metformin can be decreased when used in combination with Ritonavir. The serum concentration of Metformin can be increased when it is combined with Ranolazine. 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Metformin.